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was no observed trend in patient characteristics for the PRs except 
that all had adenocarcinoma histology. The DCR (PR or stable disease 
[SD] ≥8 weeks) in the vandetanib 100, 200 and 300 mg/day arms were 
47.1%, 38.9% and 61.1%, respectively. The adverse event (AE) proﬁle 
was consistent with that observed in previous studies of vandetanib 
in NSCLC; the most common AEs were rash (53%), diarrhea (51%), 
hypertension (47%) and asymptomatic QTc prolongation (40%). There 
was one fatal case of interstitial lung disease, which was reported 8 
days after vandetanib 300 mg was discontinued because of PD. EGFR 
gene ampliﬁcation analysis revealed 4/12 patients were FISH positive 
(SD and PD, both n=2) and 8/12 were FISH negative (PR, n=1; SD, 
n=3; and PD, n=4). Tumors from 27 patients were evaluated for EGFR 
mutations: conﬁrmed mutation (n=1; exon 19 deletion [746–750]); con-
ﬁrmed no mutation (n=21); unconﬁrmed (n=5). The mutation-positive 
patient was a female non-smoker with FISH-positive adenocarcinoma 
and a best response of PD. Among the three PRs evaluated, two had no 
EGFR mutation and one had an unconﬁrmed result. Although patient 
numbers are small, baseline plasma VEGF levels (mean ± SE) appeared 
to be lower in patients who experienced clinical beneﬁt following van-
detanib treatment: PR (68.3 ± 40.4 pg/mL, n=6) and SD (50.5 ± 13.3 
pg/mL, n=16) versus PD (128 ± 39.5 pg/mL, n=23).
Conclusions: In Japanese patients with refractory NSCLC, vandetanib 
monotherapy (100–300 mg/day) demonstrated antitumor activity with 
an acceptable safety and tolerability proﬁle. The possible relationship 
between plasma VEGF levels and clinical outcome requires further 
investigation. 
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Background: Bevacizumab (Bv) in combination with carboplatin/pacl-
itaxel received FDA approval in October 2006 for improving response 
rates and survival in ﬁrst-line treatment of advanced NSCLC patients 
without brain metastases. Brain metastases were excluded based on 
a grade 3 intracerebral hemorrhage from a hepatocellular carcinoma 
brain metastasis in the original phase I study. Since NSCLC is the most 
common cause of brain metastases, a large fraction of patients who 
might beneﬁt from Bv have never been evaluated formally. We report 
here on the safety of Bv therapy in 24 subjects with NSCLC following 
local therapy for brain metastases.
Methods: Subjects were treated on protocols AVF3671g (ATLAS) or 
AVF3752g (PASSPORT): 
The ATLAS phase III study includes platinum based chemotherapy 
with Bv, followed by Bv ± erlotinib (E) to disease progression, for 
subjects with advanced or metastatic non-squamous NSCLC. Brain 
metastases subjects had to have completed whole brain radiotherapy 
(WBRT). 
The PASSPORT phase II study includes Bv combined with ﬁrst-line or 
second-line systemic therapy in subjects with non-squamous NSCLC 
with treated brain metastases. Treatment for Brain metastases included 
radiosurgery, neurosurgery or WBRT.
Demographic characteristics, baseline disease characteristics, prior 
treatment, and on-study treatment are summarized by study. The overall 
rate of CNS hemorrhage and exact 95% conﬁdence interval using the 
method of Blyth-Still-Casella are reported. 
Results: These results pertain to data collected on subjects enrolled 
from March 2006 to follow-up through January 2007.
STUDY ATLAS - AVF3671g PASSPORT - AVF3752g
N Total: 7 Total: 19
 Men: 5 Men: 12
 Women: 2 Women: 7
Median Age 60 64
ECOG Status ECOG 0: 4 ECOG 0: 7
 ECOG 1: 3 ECOG 1: 12
Prior Therapy for WBRT: 7 WBRT alone: 12
CNS Mets  WBRT w/Radiosurgery or
  Neurosurgery: 3
  Radiosurgery alone: 4
Treatment Line 1st Line: 7 1st Line: 9
  2nd Line: 10
Concomitant Med. for CNS Mets N/A 4 subjects
 
The mean number of Bv doses (15 mg/kg/q3w) in the 24 treated sub-
jects was 4 and the median was 3 (range 1-15). 2 subjects were never 
treated with Bv. 
There were no CNS hemorrhages reported on either study (95 % upper 
conﬁdence limit: 12.6%).
On ATLAS, no subjects experienced Grade 3/4 CNS events. One on-
study death due to disease progression occurred while the subject was 
on the study treatment follow-up period.
On PASSPORT, 2 subjects experienced new onset Grade 3 CNS events 
of seizures. One of these 2 subjects was not treated with Bv; the other 
had residual resolving hemorrhage at baseline prior to study treatment. 
Conclusions: These preliminary data are encouraging with respect 
to safe administration of bevacizumab to subjects with treated brain 
metastases in these two ongoing studies. It is anticipated that data on 40 
subjects will be available at presentation; additional follow-up and sub-
jects are necessary to more precisely characterize the CNS hemorrhage 
rate and overall safety of Bv treatment in this setting. 
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Vandetanib (ZACTIMA™; ZD6474) is a once-daily oral anticancer 
drug in Phase III clinical development in a broad population of patients 
